Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,shortLongTermDebt,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,dividendDate,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,fiftyDayAverage,fiftyDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,IPA,17307418.0,19079000,,,-1204921,,-1294384,3026240,3533695,-1074046,-1074046,,-122208,,,,89463,4516000,5590046,982305,-130875,,-1294384,-1294384,6832147.0,4513492.0,11340805.0,32259261.0,386489.0,3309275.0,43600066.0,52225830.0,-24785937.0,1350340.0,8119696.0,305876.0,481705.0,15720057.0,7231688.0,305876.0,3564586.0,24486086.0,115846.0,5069486.0,1731994.0,1231395.0,1794397.0,,-262701,-372794,-136481,94730,-1999895,231211,-1123591,-128479,-717048,510815,-3158,1118997,765901,-382056,17254398.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,7.31,1630526403,-0.07000017,7.52,7.53,7.24,138402,0,ImmunoPrecise Antibodies Ltd.,PRE,us_market,-0.94851184,7.24 - 7.53,7.38,0.0,0.0,10,8,finmb_406475483,NasdaqGM,ImmunoPrecise Antibodies Ltd.,CAD,2321331,219442,2.2599998,0.4475247,5.05 - 33.34,-26.03,-0.7807439,1606089600,5.05,33.34,1615984200,1615984200,1615984200,0.037489124,8.768732,-1.4587321,-0.1663561,7.045857,0.264143,139490144,15,America/New_York,EDT,-14400000,False,False,-0.19,,,33.34,5.05,7.05,8.77,2.32M,219.44k,19.08M,,17.07M,6.73%,7.21%,135.15k,2.2,,0.71%,85.02k,,,,,,0.00%,"Nov 22, 2020",,4:1,"May 29, 2013","Apr 29, 2020","Jan 30, 2021",-18.93%,-31.16%,-9.67%,-13.93%,17.18M,1.13,11.90%,7.95M,-4.05M,-3.25M,,,15.72M,0.82,3.67M,11.37,3.39,,595.17k,776.89k,Value,V8Z 7X8,Healthcare,"ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.",Victoria,250 483 0308,BC,1609372800,Canada,http://www.immunoprecise.com,86400,3204â4464 Markham Street,Biotechnology
t-1,IPA,15574667.0,19079000,1049316.0,,-410137,,-463583,2507926,2641963,-2102442,-2102442,,-173289,,,,53446,4754545,6856987,2112582,1692305,,-463583,-463583,7373290.0,3758446.0,12624535.0,31077628.0,395854.0,4731723.0,43702163.0,50454411.0,-23491553.0,1451623.0,8129671.0,356324.0,493827.0,16840908.0,7842999.0,356324.0,3593726.0,23995651.0,115998.0,5453580.0,2066154.0,1124521.0,1389123.0,7026.0,-139294,-715207,-305815,10966645,-129536,11272460,10778284,86619,440227,561745,-106844,14386,64151,-457261,16152652.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,7.31,1630526403,-0.07000017,7.52,7.53,7.24,138402,0,ImmunoPrecise Antibodies Ltd.,PRE,us_market,-0.94851184,7.24 - 7.53,7.38,0.0,0.0,10,8,finmb_406475483,NasdaqGM,ImmunoPrecise Antibodies Ltd.,CAD,2321331,219442,2.2599998,0.4475247,5.05 - 33.34,-26.03,-0.7807439,1606089600,5.05,33.34,1615984200,1615984200,1615984200,0.037489124,8.768732,-1.4587321,-0.1663561,7.045857,0.264143,139490144,15,America/New_York,EDT,-14400000,False,False,-0.19,,,33.34,5.05,7.05,8.77,2.32M,219.44k,19.08M,,17.07M,6.73%,7.21%,135.15k,2.2,,0.71%,85.02k,,,,,,0.00%,"Nov 22, 2020",,4:1,"May 29, 2013","Apr 29, 2020","Jan 30, 2021",-18.93%,-31.16%,-9.67%,-13.93%,17.18M,1.13,11.90%,7.95M,-4.05M,-3.25M,,,15.72M,0.82,3.67M,11.37,3.39,,595.17k,776.89k,Value,V8Z 7X8,Healthcare,"ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.",Victoria,250 483 0308,BC,1609372800,Canada,http://www.immunoprecise.com,86400,3204â4464 Markham Street,Biotechnology
t-2,IPA,3479467.0,19079000,309213.0,,-368311,,-549318,2117053,2401887,-783764,-783764,,-201005,,,,181007,3764977,4548741,1363090,415453,,-549318,-549318,8103558.0,3722646.0,13504920.0,19915807.0,140007.0,4475815.0,33420727.0,38401865.0,-23027970.0,1687468.0,8332782.0,819266.0,224464.0,6062177.0,7598631.0,819266.0,3637603.0,12994926.0,127394.0,5467966.0,2530864.0,1017677.0,1726617.0,107287.0,1404013,-550149,-81035,3570085,79485,3651120,3455799,27479,408384,500259,-199034,-1808013,309350,-10566,5396295.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,7.31,1630526403,-0.07000017,7.52,7.53,7.24,138402,0,ImmunoPrecise Antibodies Ltd.,PRE,us_market,-0.94851184,7.24 - 7.53,7.38,0.0,0.0,10,8,finmb_406475483,NasdaqGM,ImmunoPrecise Antibodies Ltd.,CAD,2321331,219442,2.2599998,0.4475247,5.05 - 33.34,-26.03,-0.7807439,1606089600,5.05,33.34,1615984200,1615984200,1615984200,0.037489124,8.768732,-1.4587321,-0.1663561,7.045857,0.264143,139490144,15,America/New_York,EDT,-14400000,False,False,-0.19,,,33.34,5.05,7.05,8.77,2.32M,219.44k,19.08M,,17.07M,6.73%,7.21%,135.15k,2.2,,0.71%,85.02k,,,,,,0.00%,"Nov 22, 2020",,4:1,"May 29, 2013","Apr 29, 2020","Jan 30, 2021",-18.93%,-31.16%,-9.67%,-13.93%,17.18M,1.13,11.90%,7.95M,-4.05M,-3.25M,,,15.72M,0.82,3.67M,11.37,3.39,,595.17k,776.89k,Value,V8Z 7X8,Healthcare,"ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.",Victoria,250 483 0308,BC,1609372800,Canada,http://www.immunoprecise.com,86400,3204â4464 Markham Street,Biotechnology
t-3,IPA,-1008586.0,19079000,-221012.0,,-1484745,,-945846,2940121,1922967,-1392728,-1392728,,-163363,,,,-538899,4145023,5537751,2222056,-92017,,-945846,-945846,8185772.0,3777771.0,12177282.0,15085839.0,114575.0,3289570.0,27263121.0,34086942.0,-22478652.0,2612197.0,7908653.0,-300222.0,287551.0,2605706.0,7929767.0,-300222.0,3062807.0,7699442.0,118896.0,3748502.0,503574.0,818643.0,1353870.0,2121833.0,1018718,-37783,102599,579278,-45869,476679,686242,-318856,463603,-203372,130321,-759012,-253543,-93457,-230325.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NGM,7.31,1630526403,-0.07000017,7.52,7.53,7.24,138402,0,ImmunoPrecise Antibodies Ltd.,PRE,us_market,-0.94851184,7.24 - 7.53,7.38,0.0,0.0,10,8,finmb_406475483,NasdaqGM,ImmunoPrecise Antibodies Ltd.,CAD,2321331,219442,2.2599998,0.4475247,5.05 - 33.34,-26.03,-0.7807439,1606089600,5.05,33.34,1615984200,1615984200,1615984200,0.037489124,8.768732,-1.4587321,-0.1663561,7.045857,0.264143,139490144,15,America/New_York,EDT,-14400000,False,False,-0.19,,,33.34,5.05,7.05,8.77,2.32M,219.44k,19.08M,,17.07M,6.73%,7.21%,135.15k,2.2,,0.71%,85.02k,,,,,,0.00%,"Nov 22, 2020",,4:1,"May 29, 2013","Apr 29, 2020","Jan 30, 2021",-18.93%,-31.16%,-9.67%,-13.93%,17.18M,1.13,11.90%,7.95M,-4.05M,-3.25M,,,15.72M,0.82,3.67M,11.37,3.39,,595.17k,776.89k,Value,V8Z 7X8,Healthcare,"ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.",Victoria,250 483 0308,BC,1609372800,Canada,http://www.immunoprecise.com,86400,3204â4464 Markham Street,Biotechnology
